Details

Autor(en) / Beteiligte

• Sormani, Maria Pia
• Schiavetti, Irene
• Carmisciano, Luca
• Cordioli, Cinzia
• Filippi, Massimo
• Radaelli, Marta
• Immovilli, Paolo
• Capobianco, Marco
• De Rossi, Nicola
• Brichetto, Giampaolo
• Cocco, Eleonora
• Scandellari, Cinzia
• Cavalla, Paola
• Pesci, Ilaria
• Zito, Antonio
• Confalonieri, Paolo
• Marfia, Girolama Alessandra
• Perini, Paola
• Inglese, Matilde
• Trojano, Maria
• Brescia Morra, Vincenzo
• Tedeschi, Gioacchino
• Comi, Giancarlo
• Battaglia, Mario Alberto
• Patti, Francesco
• Salvetti, Marco

Titel

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Ist Teil von

• Neurology : neuroimmunology & neuroinflammation, 2022-01, Vol.9 (1)

Ort / Verlag

United States: Lippincott Williams & Wilkins

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim of this study is to compare COVID-19-related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and sex-matched Italian population. Hospitalization, intensive care unit (ICU) admission, and death after COVID-19 diagnosis of 1,362 patients with MS were compared with the age- and sex-matched Italian population in a retrospective observational case-cohort study with population-based control. The observed vs the expected events were compared in the whole MS cohort and in different subgroups (higher risk: Expanded Disability Status Scale [EDSS] score > 3 or at least 1 comorbidity, lower risk: EDSS score ≤ 3 and no comorbidities) by the χ test, and the risk excess was quantified by risk ratios (RRs). The risk of severe events was about twice the risk in the age- and sex-matched Italian population: RR = 2.12 for hospitalization ( < 0.001), RR = 2.19 for ICU admission ( < 0.001), and RR = 2.43 for death ( < 0.001). The excess of risk was confined to the higher-risk group (n = 553). In lower-risk patients (n = 809), the rate of events was close to that of the Italian age- and sex-matched population (RR = 1.12 for hospitalization, RR = 1.52 for ICU admission, and RR = 1.19 for death). In the lower-risk group, an increased hospitalization risk was detected in patients on anti-CD20 (RR = 3.03, = 0.005), whereas a decrease was detected in patients on interferon (0 observed vs 4 expected events, = 0.04). Overall, the MS cohort had a risk of severe events that is twice the risk than the age- and sex-matched Italian population. This excess of risk is mainly explained by the EDSS score and comorbidities, whereas a residual increase of hospitalization risk was observed in patients on anti-CD20 therapies and a decrease in people on interferon.